A Randomized, Double Blind, Placebo-Controlled Single Center Phase 2 Pilot Study to Assess the Safety and Efficacy of Off-label Subcutaneous Administration of Erenumab-aooe in Patients With Temporomandibular Disorder
Latest Information Update: 12 Aug 2024
At a glance
- Drugs Erenumab (Primary)
- Indications Temporomandibular joint dysfunction syndrome
- Focus Proof of concept; Therapeutic Use
- 23 Jan 2024 Status changed from active, no longer recruiting to completed.
- 16 Nov 2023 Planned End Date changed from 28 Dec 2023 to 28 Jan 2024.
- 16 Nov 2023 Planned primary completion date changed from 30 Nov 2023 to 30 Dec 2023.